Intradermal versus subcutaneous immunization: Effects of administration route using a lipid-PLGA hybrid nanoparticle tuberculosis vaccine

Tuberculosis (TB) remains a significant global health challenge, latently affecting around a quarter of the global population. The sole licensed TB vaccine, Mycobacterium bovis Bacillus Calmette-Guérin (BCG), shows variable efficacy, particularly among adolescents and adults, underscoring the pressi...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pharmaceutical sciences Vol. 205; p. 106995
Main Authors: Szachniewicz, M.M., van den Eeden, S.J.F., van Meijgaarden, K.E., Franken, K.L.M.C., van Veen, S., Geluk, A., Bouwstra, J.A., Ottenhoff, T.H.M.
Format: Journal Article
Language:English
Published: Netherlands Elsevier B.V 01.02.2025
Subjects:
Adjuvant
Animals
Antigens, Bacterial - administration & dosage
Antigens, Bacterial - immunology
Bacillus Calmette-Guérin
Bacterial Proteins - administration & dosage
Bacterial Proteins - immunology
Cationic lipid−PLGA hybrid nanoparticles
Female
Immunogenicity
Injections, Intradermal
Injections, Subcutaneous
Lipids - chemistry
Mice
Mice, Inbred C57BL
Nanoparticles - administration & dosage
Nanoparticles - chemistry
Polylactic Acid-Polyglycolic Acid Copolymer - administration & dosage
Polylactic Acid-Polyglycolic Acid Copolymer - chemistry
Subunit vaccine
Tuberculosis
Tuberculosis - immunology
Tuberculosis - prevention & control
Tuberculosis Vaccines - administration & dosage
Tuberculosis Vaccines - chemistry
Tuberculosis Vaccines - immunology
Vaccine delivery system
NP
Ag
HRP
MHC
CpG ODN
TNF
Cationic lipid−PLGA hybrid nanoparticles
IFN
PDI
Subunit vaccine
FDR
FBS
pH
Adjuvant
TLR
DOPC
i.d
KLRG1
DOPE
Th1/Th2
UMAP
CD
DOBAQ
BCG
MDR-TB
s.c
IQR
AER
rpm
TB
Bacillus Calmette-Guérin
Tuberculosis
CCR
PLGA
Immunogenicity
APC
PE
EPC
Mtb
CXCR
Vaccine delivery system
HLA
LUMC
MPLA
PD-1
Ig
PCR
DC
ISSN:0928-0987, 1879-0720, 1879-0720
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tuberculosis (TB) remains a significant global health challenge, latently affecting around a quarter of the global population. The sole licensed TB vaccine, Mycobacterium bovis Bacillus Calmette-Guérin (BCG), shows variable efficacy, particularly among adolescents and adults, underscoring the pressing need for more effective vaccination strategies. The administration route is crucial for vaccine efficacy, and administration via the skin, being rich in immune cells, may offer advantages over conventional subcutaneous routes, which lack direct access to abundant antigen-presenting cells. This study compared the immunogenic effects of intradermal versus subcutaneous administration of a candidate TB vaccine delivering a Ag85B-ESAT6-Rv2034 (AER) multiphase fusion recombinant protein, in lipid-poly(D,L-lactic-co-glycolic acid) (lipid-PLGA) nanoparticles in mice. In-depth evaluation of immune responses in splenocytes was performed using 27-marker spectral flow cytometry. Both routes elicited significant T-cell responses. However, intradermal administration uniquely increased polyfunctional CD4+ and CD8+ T-cells producing IL-2, IFNγ, and TNFα, associated with protection against TB. Additionally, it significantly increased CD69+ B-cell counts and induced higher AER-specific antibody titers, particularly IgG2a. These results underscore the superior immunogenic potential of intradermal vaccine administration by effectively inducing immune cells associated with TB protection, highlighting its significance in the development of new vaccine strategies. [Display omitted]
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0928-0987
1879-0720
1879-0720
DOI:10.1016/j.ejps.2024.106995